Toronto Dominion Bank acquired a new stake in Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 1,436,900 shares of the company's stock, valued at approximately $14,355,000. Toronto Dominion Bank owned about 6.41% of Oaktree Acquisition Corp. III Life Sciences as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Shaolin Capital Management LLC acquired a new stake in shares of Oaktree Acquisition Corp. III Life Sciences in the fourth quarter valued at $5,478,000. AQR Arbitrage LLC acquired a new stake in Oaktree Acquisition Corp. III Life Sciences in the 4th quarter valued at about $19,743,000. K2 Principal Fund L.P. bought a new position in shares of Oaktree Acquisition Corp. III Life Sciences in the fourth quarter worth about $1,945,000. Lighthouse Investment Partners LLC acquired a new position in shares of Oaktree Acquisition Corp. III Life Sciences during the fourth quarter worth approximately $3,039,000. Finally, Sculptor Capital LP acquired a new position in shares of Oaktree Acquisition Corp. III Life Sciences during the fourth quarter worth approximately $2,490,000.
Oaktree Acquisition Corp. III Life Sciences Price Performance
Shares of Oaktree Acquisition Corp. III Life Sciences stock opened at $10.48 on Tuesday. The firm has a 50 day moving average of $10.24. Oaktree Acquisition Corp. III Life Sciences has a fifty-two week low of $9.95 and a fifty-two week high of $10.85.
Oaktree Acquisition Corp. III Life Sciences Company Profile
(
Free Report)
Oaktree Acquisition Corp. III Life Sciences is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 1995 and is headquartered in Los Angeles, CA.
Read More
Want to see what other hedge funds are holding OACC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Oaktree Acquisition Corp. III Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oaktree Acquisition Corp. III Life Sciences wasn't on the list.
While Oaktree Acquisition Corp. III Life Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
